会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明授权
    • Antiplatelet agent
    • 抗血小板药
    • US06489290B2
    • 2002-12-03
    • US09381261
    • 1999-12-07
    • Joseph LoscalzoAida Inbal
    • Joseph LoscalzoAida Inbal
    • A61K3800
    • C07K14/355A61K38/00
    • This invention combines the unique antiplatelet effects of S-nitrosothiols and the antiadhesive properties of fragments of von Willebrand (vWF) in the A1 domain to provide unique molecules that exploit both of these properties. Preferred molecules comprise a fragment of A1 (Ala 444-Asn 730) in which arginine at position 545 is replaced by cysteine (the most frequent von Willebrand disease type 2b mutation) that has been discovered to impair platelet adhesion, and to inhibit an antithrombotic activity in vivo. This cysteine residue may be S-nitrosated to produce a novel molecule that has the potential for impairing platelet adhesion as well as activation/aggregation, and such molecules form the basis of a novel therapeutic method for impairing platelet responses following vascular injury or in other thrombotic disorders according to this invention.
    • 本发明结合了S-亚硝基硫醇的独特的抗血小板作用和缬沙坦(vWF)片段在A1结构域中的抗粘附性,以提供独特的分子,利用这两种特性。 优选的分子包含A1(Ala 444-Asn 730)的片段,其中545位的精氨酸被已被发现损伤血小板粘附的半胱氨酸(最常见的血管性血友病血型B型突变)代替,并且抑制抗血栓形成活性 体内。 该半胱氨酸残基可以被S-亚硝基化以产生具有损害血小板粘附和活化/聚集的潜力的新分子,并且这些分子形成用于损伤血管损伤或其它血栓形成后血小板反应的新型治疗方法的基础 根据本发明的病症。